Daily Respiratory Research Analysis
Three high-impact respiratory studies stand out: a prospective study from Bangladesh quantifies RSV’s hospital burden and simulates the potential system-level benefits of maternal vaccination and nirsevimab; a Lancet Global Health meta-analysis shows substantial persistent lung function impairment after pulmonary tuberculosis; and a multicenter ICU cohort suggests high-flow nasal cannula may reduce 90-day mortality in COPD patients with COVID-19-related ARDS.
Summary
Three high-impact respiratory studies stand out: a prospective study from Bangladesh quantifies RSV’s hospital burden and simulates the potential system-level benefits of maternal vaccination and nirsevimab; a Lancet Global Health meta-analysis shows substantial persistent lung function impairment after pulmonary tuberculosis; and a multicenter ICU cohort suggests high-flow nasal cannula may reduce 90-day mortality in COPD patients with COVID-19-related ARDS.
Research Themes
- RSV burden and prevention strategies in resource-limited settings
- Post-tuberculosis lung disease and long-term pulmonary impairment
- Noninvasive respiratory support in COPD with COVID-19 ARDS
Selected Articles
1. Health-care burden related to respiratory syncytial virus in a resource-constrained setting: a prospective observational study.
Prospective hospital-wide surveillance in Bangladesh showed RSV accounted for 20.5% of respiratory admissions with 1.9% in-hospital mortality and substantial bed-day use. Children denied admission due to bed shortages had significantly higher mortality (HR 1.56). Queueing-model simulations suggested maternal prefusion-F vaccination and nirsevimab could reduce admission denials and prevent deaths.
Impact: This study quantifies RSV’s system-level burden in a low-resource context and provides actionable estimates for vaccine and monoclonal antibody impact on admissions and mortality.
Clinical Implications: Health systems in similar settings should prioritize RSV prevention via maternal immunization and targeted nirsevimab, and incorporate capacity planning to mitigate admission denials and excess mortality.
Key Findings
- RSV positivity among respiratory admissions: 20.5% (1261/6149) with median age 3 months and median LOS 5 days.
- In-hospital mortality among RSV-positive children: 1.9% (24/1261).
- Admission denial due to bed shortages increased mortality risk (HR 1.56; neonates HR 2.27).
- Simulations estimated reductions in admission denials by 677 (maternal vaccine) and 1289 (nirsevimab) and prevention of 130 and 258 deaths, respectively.
Methodological Strengths
- Prospective, hospital-wide surveillance using WHO case definitions with large sample size.
- Use of survival analysis for denied vs admitted outcomes and Monte Carlo queueing-model simulations for intervention impact.
Limitations
- Single-country, single-hub hospital setting may limit generalizability to other LMICs.
- Model-based projections rely on assumptions about coverage and effectiveness; unmeasured confounding in denial vs admission comparisons.
Future Directions: Implement real-world evaluations of maternal RSV vaccination and nirsevimab programs with coverage, equity, and cost-effectiveness endpoints; extend queueing simulations to multi-hospital networks.
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of paediatric hospital admissions worldwide, straining health systems. A lack of data on the burden of RSV infections and the impact on health systems in resource-limited settings hinders evidence-based policy decisions. Here, we aimed to assess RSV's burden on the health system in Bangladesh. METHODS: From January to December, 2019, we conducted a prospective study at Bangladesh's largest paediatric hospital among children aged 0-59 months admitted with a possible respiratory infection, as guided by the WHO RSV hospital-based surveillance case definition. Outcomes for RSV-positive children younger than 5 years were analysed. We also followed up outcomes of children denied hospitalisation due to bed shortages. Adjusted hazard ratios for children denied admission versus admitted were estimated using survival analysis. Monte Carlo simulations with a queueing model were used to estimate the effects of RSV prefusion F maternal vaccine or nirsevimab on admission denials and mortality. FINDINGS: Of 40 664 children admitted, 31 692 were younger than 5 years; 19 940 were in study wards. Among 7191 admitted with possible respiratory infections, 6149 (85·5%) had nasopharyngeal swabs taken, with 1261 (20·5%) testing RSV-positive. The median age of children who tested positive for RSV was 3·0 months (IQR 1·0-8·0), with a median hospital stay of 5 days (IQR 4-8); 24 (1·9%) of 1261 died in hospital. 8274 (5·5%) of 151 110 bed days were for children who were positive for RSV. Additionally, of 9169 children denied admission, outcomes were tracked for 3928 and compared with 2845 admitted. The hazard ratio for death was 1·56 (95% CI 1·34 to 1·81) for children denied versus admitted, being highest for neonates at 2·27 (1·87 to 2·75). RSV prefusion F maternal vaccine or nirsevimab could have reduced denials by 677 (95% prediction interval 63 to 1347) and 1289 (684 to 1865), respectively, potentially preventing 130 (-60 to 322) and 258 (32 to 469) deaths. INTERPRETATION: RSV strains health care in Bangladesh, increasing mortality risks. Preventive interventions could lessen its impact, boosting health-care capacity and child health in resource-limited settings. FUNDING: The Bill & Melinda Gates Foundation.
2. Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis.
This PRISMA-based meta-analysis of 19 studies (75,960 participants) demonstrates that individuals with prior pulmonary tuberculosis have significantly reduced spirometric values (e.g., FEV1 and FVC) compared with controls, consistent across adjustment levels. Patterns suggest increased obstructive and restrictive ventilatory defects post-TB.
Impact: Defines the magnitude and pervasiveness of post-TB lung impairment, supporting structured follow-up and rehabilitation strategies globally.
Clinical Implications: Routine post-TB spirometry and referral to pulmonary rehabilitation should be integrated into TB programs; clinicians should anticipate mixed ventilatory defects and address comorbid risk factors (e.g., smoking).
Key Findings
- Meta-analysis of 19 studies (n=75,960; 7,447 with prior TB) shows consistent reductions in spirometric indices (e.g., FEV1, FVC) versus healthy controls.
- Findings were robust across studies despite differing levels of standardization/adjustment.
- Ventilatory defect patterns indicate elevated obstructive and restrictive abnormalities after TB.
Methodological Strengths
- Systematic search across three databases with comparative design inclusion.
- Large combined sample size enabling precise estimation across multiple spirometric endpoints.
Limitations
- Heterogeneity in study designs, populations, and spirometric standardization likely present.
- Limited data on longitudinal recovery trajectories and effect modifiers (e.g., treatment era, HIV co-infection).
Future Directions: Prospective longitudinal cohorts to map recovery and decline, define phenotypes of post-TB lung disease, and test targeted rehabilitation and pharmacologic interventions.
BACKGROUND: Although post-tuberculosis lung disease poses a substantial threat to individuals who have recovered from pulmonary tuberculosis, data showing objective functional impairment in such people are scarce. We did a systematic review and meta-analysis to estimate respiratory impairment after pulmonary tuberculosis disease and examine differences in ventilatory defects. METHODS: We systematically searched Embase, MEDLINE, and CINAHL from Jan 1, 2000, to Dec 13, 2024. We included any study design with data on lung function tests in individuals with a previous diagnosis of pulmonary tuberculosis versus healthy controls. Outcomes extracted from eligible studies included forced expiratory volume in 1 s (FEV FINDINGS: Of the 5594 publications found, data from 19 studies were included for meta-analyses, reporting on 75 960 individuals of whom 7447 had past pulmonary tuberculosis. All studies reporting absolute values, using various levels of adjustment or standardisation, showed that previous pulmonary tuberculosis had a negative effect across all spirometric values: FEV INTERPRETATION: People who recover from pulmonary tuberculosis have significantly decreased lung function compared with controls, with FEV FUNDING: Breathing Matters.
3. Outcomes and predictors of mortality in patients with severe COVID-19 and COPD admitted to ICU: A multicenter study.
Across 55 ICUs, COPD patients with COVID-19 had higher mortality (50%). In those with ARDS, high-flow nasal cannula use was associated with reduced 90-day mortality (HR 0.54). Mortality correlated with immune dysregulation (lower IgG, higher viral load, TNF-α, VCAM-1, Fas).
Impact: Provides multicenter evidence supporting HFNC use in COPD patients with COVID-19 ARDS and identifies immunologic correlates of mortality for potential targeting.
Clinical Implications: Consider HFNC as a frontline noninvasive support in COPD patients with COVID-19 ARDS when feasible, with close monitoring; biomarker profiles may inform risk stratification and adjunctive therapies.
Key Findings
- In 6512 ICU COVID-19 patients across 55 centers, COPD subgroup (n=328) had 50% mortality vs 33% in other CRDs and no-CRD groups.
- HFNC use in COPD with ARDS was associated with reduced 90-day mortality (HR 0.54; 95% CI 0.31–0.95).
- Lower IgG and higher viral load, TNF-α, VCAM-1, and Fas were associated with mortality in COPD patients.
Methodological Strengths
- Large multicenter cohort with standardized data capture and propensity score matching.
- Integration of clinical outcomes with immunologic biomarkers for mechanistic insight.
Limitations
- Observational design with potential residual confounding and treatment-selection bias.
- COPD subgroup size smaller than entire cohort; findings from Spanish ICUs may limit generalizability.
Future Directions: Randomized or pragmatic trials comparing HFNC vs alternative support in COPD with viral ARDS; validation of biomarker-guided risk stratification and therapy.
BACKGROUND: High mortality rates among patients with chronic obstructive pulmonary disease (COPD) admitted to intensive care units (ICUs) during the COVID-19 pandemic highlight the need for tailored clinical management strategies. STUDY DESIGN AND METHODS: Epidemiological, clinical, and laboratory data were collected in REDCap for 6512 patients hospitalized with COVID-19 across 55 Spanish ICUs. Patients were stratified into three groups: those with COPD, those with other chronic respiratory diseases (CRD), and those without respiratory comorbidities (No CRD). The primary outcome was to determine clinical predictors for 90-day mortality, focusing on the COPD group. A propensity score matching (PSM) method was applied to analyze the effects of respiratory support, biomarkers, and immunomarkers. RESULTS: Patients with COPD (n = 328) exhibited a 50% mortality rate compared to 33% of those with other chronic respiratory diseases (CRD, n = 547), and those without respiratory comorbidities (No CRD, n = 5124). Among COPD patients, 95% of whom had Acute Respiratory Distress Syndrome (ARDS) due to COVID-19, the use of a high-flow nasal cannula (HFNC) was associated with reduced 90-day mortality (hazard ratio: 0.54 (95% Confidence Interval [0.31-0.95]). At a molecular scale, lower IgG levels but higher viral load and TNF-alpha, Vascular Cell Adhesion Molecule-1 (VCAM-1), and Fas Cell Surface Death Receptor (Fas) were associated with mortality in the COPD group. CONCLUSIONS: In COPD patients with ARDS due to COVID-19, the use of HFNC was associated with a better prognosis. The dysregulation in biomarkers and immunomarkers in COPD patients and its association with mortality highlight the need for further targeted therapeutic strategies.